Efficacy of Reboxetine and Methylphenidate Treatment on Attentional, Sensory and Emotional Dysregulation in Adults With PTSD
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Methylphenidate, Reboxetine, Placebo, Placebo.
- Who it may be relevant to
- Registry conditions: Posttraumatic Stress Disorder. Basic parameters: 20 years — 60 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Israel
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
The Relation Between Attentional, Sensory and Emotional Dysregulation in Adults With Posttraumatic Stress Disorder: a Double-blind, Placebo-controlled Randomized Controlled Trial of the Combined Treatment With Reboxetine and Methylphenidate
Overview
Up-to-date, no studies have examined the attentional, sensory and emotional processing (difficulties) among patients diagnosed with Posttraumatic Stress Disorder (PTSD). In addition, the efficiency of drug treatments that focus on the noradrenergic and dopaminergic, and thus influence attention processing and PTSD symptoms through these pathways, have only briefly been investigated. There is well-established and long-standing evidence for the involvement of dopamine and noradrenaline in attentional function. This previously led to an investigation by the investigator's research lab in which the investigators hypothesized the involvement of an attentional disorder would influence PTSD symptoms in a rat model. Based on these results, the current study aims to characterize attentional deficits in patients with PTSD, as well as the correlation between attention, emotional regulation and sensory processing. The investigators do this partially by conducting a case-control study and through a subsequent double-blind RCT (with only the cases). The patients will be either treated with reboxetine + methylphenidate or placebo.
Detailed description
Posttraumatic stress disorder (PTSD) is a highly impairing psychiatric disorder, characterized by re-experiencing, avoidance behaviour, emotional numbing, and hyperarousal after traumatic exposure. Current treatments mainly focus on non-cognitive symptoms and are only partially effective: one third of PTSD patients will find symptoms to be chronic and progressive; highly impacting daily function and quality of life. Arising evidence suggests a correlation between impaired attention, sensory dysfunction, and PTSD symptoms. Thus, the importance of combined treatment, focused on concentration difficulties as often found PTSD, has been suggested. Two suggested leads are reboxetine and methylphenidate.
Hypothesising that impaired attentional and sensory processing induces re-experiencing with avoidance and hyperarousal as coping strategies, the investigators aim to elucidate the neuro-dysregulation characteristics of each of the PTSD symptoms, with focus on attention, executive function and sensory processing, and relate to their implications on daily life function, following a novel combined treatment strategy of reboxetine and methylphenidate (Ritalin).
A case-control study will be conducted, including 53adult patients with PTSD and 53 matched healthy controls. First, a baseline measure will be performed amongst all participants to create a population profile. Then, patients will be randomised into an active treatment group (n=27) and a placebo group (n=26) for a double-blind randomized controlled trial, investigating the effect of a 3-week treatment with reboxetine 4mg per day and a one-week addition of Ritalin 10mg twice a day.
This research will include established and innovative neurophysiological measures and questionnaires. A PTSD symptom profile will be created combining the Clinician-Administered Posttraumatic Stress Disorder Scale and Posttraumatic Stress Disorder Symptom Scale. Brain activity will be measured using functional near-infrared spectroscopy (fNIR) or electroencephalography, with the Auditory Sustained Attention Test (ASAT) and Electrodermal Activity (EDA). Together with the Conners' Adult Attention Deficit Hyperactivity Disorder (ADHD) Rating Scale - Short Version, the ASAT and EDA will create an attentional profile. Furthermore, a sensory profile consisting of the Adolescent/Adult Sensory Profile Questionnaire, and an executive function profile measured with the Behavior Rating Inventory of Executive Function will be created. Finally, in order to relate to individual experiences in real-life context, this research measures activities through the Daily Living Questionnaire and quality of life with the World Health Organization Quality of Life Instrument.
Using a translational research paradigm, this research is one of the first to investigate neuro-dysregulation in PTSD with a focus on sensory processing and executive function, with emphasis on attention and behaviour. It is also the first research to integrate the fNIR with the ASAT and EDA, thus contributing to the technological advancing of clinical research. This research will gather innovative data that may offer new explanations of PTSD symptoms and allow for further development of treatment interventions needed to reduce the burden of disease and optimise quality of life.
Interventions
- Drug Methylphenidate
Ritalin 10mg - Drug Reboxetine
Reboxetine 4mg - Drug Placebo
Placebo matched to Reboxetine - Drug Placebo
Placebo matched to Ritalin
Primary outcome measures
- Change in Clinician-Administered Posttraumatic Stress Disorder Scale for the Diagnostic and Statistical Manual (DSM)-5 (CAPS-5) between baseline score (before treatment) and score on day 26 (after treatment) [Time frame: Day 1 and day 26]
Secondary outcome measures (10)
- Posttraumatic Stress Disorder Symptom Scale (PSS-SR5) [Time frame: Day 1 and day 26]
- Conner's Adult ADHD Rating Scales - Self Report: short version (CAARS-S:S) [Time frame: Day 1 and day 26]
- Electroencephalography (EEG) [Time frame: Day 1, day 21 and day 26]
- Functional near-infrared spectroscopy (fNIRS) [Time frame: Day 1, day 21 and day 26]
- Electrodermal Activity (EDA) [Time frame: Day 1, day 21 and day 26]
- Auditory Sustained Attention Test (ASAT) [Time frame: Day 1, day 21 and day 26]
- Adolescent/Adult Sensory Profile Questionnaire (AASP) [Time frame: Day 1 and day 26]
- Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A) [Time frame: Day 1 and day 26]
- Daily Life Questionnaire (DLQ) [Time frame: Day 1 and day 26]
- World Health Organization Quality of Life Questionnaire - BREF (WHOQOL-BREF) [Time frame: Day 1 and day 26]
Eligibility criteria
Inclusion criteria
- diagnosed with PTSD according to DSM-IV or DSM-5 criteria
- current treatment at the outpatient facilities of Lev HaSharon Netanya Adult Clin
- age between 20 and 60 years
- PTSD diagnosis at least one month prior to study inclusion
- no present-day re-exposure to the traumatic event
- any psychotropic drug therapy that is being administered must be at a fixed dose for at least one month prior to the study conductance
Exclusion criteria
- comorbid major psychiatric disorder, e.g. psychotic disorder, unipolar or bipolar disorder, borderline personality disorder, or active suicidal ideation,
- ADHD diagnosis,
- significant or severe systematic disease that limits normal activity, e.g. autoimmune disease, AIDS or renal failure,
- cardiovascular disease, e.g. hypertension, atrioventricular (AV) block, bradycardia, or conduction disorder,
- severe disease that is a threat to life, e.g. acute myocardial infarction, respiratory failure, or cancer,
- nervous system impairment, e.g. multiple sclerosis, Alzheimer's disease, Parkinson's disease, epilepsy, or stroke,
- previous or current severe traumatic brain injury,
- glaucoma,
- impaired hearing,
- pregnancy or breastfeeding during study inclusion,
- active substance dependency including regular use of medical cannabis,
- use of steroid medication in the two months prior to study conductance,
- use of medication that may affect the function of the central nervous system,
- failure to complete all research steps
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Triple blind
- Primary purpose
- Treatment
Study locations
Israel · 3 centers
- Emek Medical Center — Afula
- University of Haifa — Haifa
- Lev HaSharon Mental Health Center — Netanya
Publications
- Aga-Mizrachi S, Cymerblit-Sabba A, Gurman O, Balan A, Shwam G, Deshe R, Miller L, Gorodetsky N, Heinrich N, Tzezana O, Zubedat S, Grinstein D, Avital A. Methylphenidate and desipramine combined treatment improves PTSD symptomatology in a rat model. Transl Psychiatry. 2014 Sep 23;4(9):e447. doi: 10.1038/tp.2014.82. PMID 25247592
- McAllister TW, Zafonte R, Jain S, Flashman LA, George MS, Grant GA, He F, Lohr JB, Andaluz N, Summerall L, Paulus MP, Raman R, Stein MB. Randomized Placebo-Controlled Trial of Methylphenidate or Galantamine for Persistent Emotional and Cognitive Symptoms Associated with PTSD and/or Traumatic Brain Injury. Neuropsychopharmacology. 2016 Apr;41(5):1191-8. doi: 10.1038/npp.2015.282. Epub 2015 Sep 11. PMID 26361060
Identifiers
NCT: NCT05133804 · LH9/2019